# To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Source: https://onco.cc/trials/nct04853342/  
OnCo record `nct04853342` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Furmonertinib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., now recruiting.

## Summary

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy is a phase 3 interventional study registered as NCT04853342 by Allist Pharmaceuticals, Inc., with 318 participants planned, started 2021-06-07 and due to reach its primary completion in 2026-12. Interventions recorded: Drug: Furmonertinib 80 mg and Furmonertinib 80 mg placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04853342
- Phase: 3
- Setting: A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, Study to Assess the Efficacy and Safety of Furmonertinib (AST2818) Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
- Sponsor: Allist Pharmaceuticals, Inc.
- Enrolled: 318

## Sources

- ClinicalTrials.gov NCT04853342: https://clinicaltrials.gov/study/NCT04853342

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Furmonertinib](https://onco.cc/drugs/furmonertinib/)
- companies: [Shanghai Allist Pharmaceuticals](https://onco.cc/companies/allist/)

---
JSON: https://onco.cc/api/v1/entities/nct04853342.json